Back to Archived News
Uroplasty Announces Issuance of New Patent for Urgent PC System Single-Use Lead Set
Tuesday, March 23, 2010
Minneapolis, MN -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,668,598 covering the stimulation method used in the Urgent® PC Neuromodulation System. The Urgent PC Neuromodulation System is a nonsurgical system for treatment of urinary urgency, urinary frequency and urinary urge incontinence, symptoms often associated with overactive bladder.
"This newly-issued patent covers the delivery of current to the sacral nerve through percutaneous electrical stimulation of the tibial nerve with our unique, disposable lead set," said David Kaysen, President and CEO. "This newly-issued patent enhances our strong patent protection for Urgent PC, which two recently published studies have shown to be effective for the treatment of patients with urinary symptoms often associated with overactive bladder. We are very pleased to have this additional protection on the unique, single-use feature of the stimulation method used in our Urgent PC System."
About the Urgent® PC Neuromodulation System
The Urgent PC Neuromodulation System is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urinary urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms. Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent® PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urinary urge incontinence - symptoms often associated with overactive bladder.
We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Macroplastique may be used for patients even if other incontinence treatments such as a sling procedure have failed. For complete information regarding Macroplastique, please refer to the Instructions for Use brochure available at the Uroplasty website at www.uroplasty.com.
This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, our ability to continue to grow our Urgent PC sales is subject to a number risks, including the risk that third-party payors will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses for Urgent PC treatments.
Back to Archived News